Literature DB >> 24791940

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

Maria Angelica Cortez1, David Valdecanas1, Xiaochun Zhang1, Yanai Zhan2, Vikas Bhardwaj1, George A Calin3, Ritsuko Komaki4, Dipak K Giri5, Caio C Quini6, Tatiana Wolfe1, Heidi J Peltier7, Andreas G Bader7, John V Heymach8, Raymond E Meyn1, James W Welsh9.   

Abstract

The microRNA (miR)-200s and their negative regulator ZEB1 have been extensively studied in the context of the epithelial-mesenchymal transition. Loss of miR-200s has been shown to enhance cancer aggressiveness and metastasis, whereas replacement of miR-200 miRNAs has been shown to inhibit cell growth in several types of tumors, including lung cancer. Here, we reveal a novel function of miR-200c, a member of the miR-200 family, in regulating intracellular reactive oxygen species signaling and explore a potential application for its use in combination with therapies known to increase oxidative stress such as radiation. We found that miR-200c overexpression increased cellular radiosensitivity by direct regulation of the oxidative stress response genes PRDX2, GAPB/Nrf2, and SESN1 in ways that inhibits DNA double-strand breaks repair, increase levels of reactive oxygen species, and upregulate p21. We used a lung cancer xenograft model to further demonstrate the therapeutic potential of systemic delivery of miR-200c to enhance radiosensitivity in lung cancer. Our findings suggest that the antitumor effects of miR-200c result partially from its regulation of the oxidative stress response; they further suggest that miR-200c, in combination with radiation, could represent a therapeutic strategy in the future.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24791940      PMCID: PMC4435581          DOI: 10.1038/mt.2014.79

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  41 in total

1.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

2.  Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs.

Authors:  V Stresing; E Baltziskueta; N Rubio; J Blanco; María C Arriba; J Valls; M Janier; P Clézardin; R Sanz-Pamplona; C Nieva; M Marro; D Petrov; P Dmitri; A Sierra
Journal:  Oncogene       Date:  2012-03-19       Impact factor: 9.867

3.  Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).

Authors:  Prakash Chinnaiyan; Shyhmin Huang; Geetha Vallabhaneni; Eric Armstrong; Sooryanarayana Varambally; Scott A Tomlins; Arul M Chinnaiyan; Paul M Harari
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

4.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

5.  Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability.

Authors:  Andrei V Budanov; Tzipora Shoshani; Alexander Faerman; Elena Zelin; Iris Kamer; Hagar Kalinski; Svetlana Gorodin; Alla Fishman; Ayelet Chajut; Paz Einat; Rami Skaliter; Andrei V Gudkov; Peter M Chumakov; Elena Feinstein
Journal:  Oncogene       Date:  2002-09-05       Impact factor: 9.867

6.  Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

Authors:  James W Welsh; Ritsuko Komaki; Arya Amini; Mark F Munsell; Wyatt Unger; Pamela K Allen; Joe Y Chang; Jeffrey S Wefel; Susan L McGovern; Linda L Garland; Su S Chen; Jamie Holt; Zhongxing Liao; Paul Brown; Erik Sulman; John V Heymach; Edward S Kim; Baldassarre Stea
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

7.  Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis.

Authors:  Evangelos Andreakos; Una Rauchhaus; Athanassios Stavropoulos; Gerold Endert; Volkmar Wendisch; Amina S Benahmed; Stavros Giaglis; James Karras; Sam Lee; Hans Gaus; C Frank Bennett; Richard O Williams; Paschalis Sideras; Steffen Panzner
Journal:  Arthritis Rheum       Date:  2009-04

8.  ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin.

Authors:  Benoît Biteau; Jean Labarre; Michel B Toledano
Journal:  Nature       Date:  2003-10-30       Impact factor: 49.962

9.  MiR-200c increases the radiosensitivity of non-small-cell lung cancer cell line A549 by targeting VEGF-VEGFR2 pathway.

Authors:  Liangliang Shi; Sheng Zhang; Hongge Wu; Lilin Zhang; Xiaofang Dai; Jianli Hu; Jun Xue; Tao Liu; Yichen Liang; Gang Wu
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

10.  A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells.

Authors:  Ulrike Burk; Jörg Schubert; Ulrich Wellner; Otto Schmalhofer; Elizabeth Vincan; Simone Spaderna; Thomas Brabletz
Journal:  EMBO Rep       Date:  2008-05-16       Impact factor: 8.807

View more
  82 in total

Review 1.  Missing link between microRNA and prostate cancer.

Authors:  Balraj Singh Gill; Jimi Marin Alex; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2016-01-28

2.  Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3.

Authors:  Jie Luo; Bin Chen; Xian-Xiu Ji; Song-Wen Zhou; Di Zheng
Journal:  Tumour Biol       Date:  2015-08-28

Review 3.  Tracking miRNAs' footprints in tumor-microenvironment interactions: Insights and implications for targeted cancer therapy.

Authors:  Nazila Nouraee; Seyed Javad Mowla; George A Calin
Journal:  Genes Chromosomes Cancer       Date:  2015-03-31       Impact factor: 5.006

4.  Examining the effect of gene reduction in miR-95 and enhanced radiosensitivity in non-small cell lung cancer.

Authors:  W Ma; C-n Ma; X-d Li; Y-j Zhang
Journal:  Cancer Gene Ther       Date:  2016-02-26       Impact factor: 5.987

Review 5.  The emerging molecular machinery and therapeutic targets of metastasis.

Authors:  Yutong Sun; Li Ma
Journal:  Trends Pharmacol Sci       Date:  2015-05-01       Impact factor: 14.819

6.  miR-8 modulates cytoskeletal regulators to influence cell survival and epithelial organization in Drosophila wings.

Authors:  Kelsey Bolin; Nicholas Rachmaninoff; Kea Moncada; Katharine Pula; Jennifer Kennell; Laura Buttitta
Journal:  Dev Biol       Date:  2016-02-21       Impact factor: 3.582

Review 7.  miRNA nanotherapeutics for cancer.

Authors:  Aditya Ganju; Sheema Khan; Bilal B Hafeez; Stephen W Behrman; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Drug Discov Today       Date:  2016-11-01       Impact factor: 7.851

8.  Therapeutic Delivery of miR-29b Enhances Radiosensitivity in Cervical Cancer.

Authors:  Tingting Zhang; Xiang Xue; Huixia Peng
Journal:  Mol Ther       Date:  2019-04-11       Impact factor: 11.454

Review 9.  Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Authors:  Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney
Journal:  Chem Rev       Date:  2018-01-11       Impact factor: 60.622

Review 10.  MicroRNA as tools and therapeutics in lung cancer.

Authors:  Jennifer F Barger; S Patrick Nana-Sinkam
Journal:  Respir Med       Date:  2015-02-19       Impact factor: 3.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.